Roivant Surges on ‘Exceptional’ Results; Bristol Myers Touts First-of-Its-Kind CAR-T Therapy

Roivant Sciences soars 19% on positive mosliciguat trial results (ROIV:NASDAQ)

Roivant Sciences (ROIV) jumps 19% to a 52-week high after mosliciguat hit Phase 2 pulmonary hypertension endpoints—get the latest ROIV stock update and key...

Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy

One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key study.

Roivant lung disease drug hits mid-stage study goals

Roivant reports its experimental drug mosliciguat for a type of pulmonary hypertension achieved goals of mid-stage study.

Roivant reports Phase 2 win for lung disease drug that it got from Bayer

Roivant Sciences said Tuesday its inhaled drug candidate has passed a mid-stage test in interstitial lung disease, surpassing Wall Street’s benchmarks for success. In the Phase 2 trial, mosliciguat met the primary endpoint of change ...